Consensus on management of drug-drug interaction with direct-acting antiviral agents in chronic hepatitis C.
10.3760/cma.j.issn.1007-3418.2018.07.001
- VernacularTitle:丙型肝炎直接抗病毒药物应用中的药物相互作用管理专家共识
- Collective Name:Chinese Foundation for Hepatitis Prevention and Control;Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Infectious Diseases, Chinese Medical Association
- Publication Type:Journal Article
- Keywords:
Consensus;
Direct-acting antiviral agents;
Drug-drug interaction;
Hepatitis C;
Management
- MeSH:
Antiviral Agents/therapeutic use*;
Consensus;
Databases, Factual;
Drug Interactions;
Hepatitis C, Chronic/drug therapy*;
Humans
- From:
Chinese Journal of Hepatology
2018;26(7):481-488
- CountryChina
- Language:Chinese
-
Abstract:
Approved direct-acting antiviral agents (DAA ) in chronic hepatitis C were introduced. Metabolism and pharmacokinetics data of DAAs were analyzed. Comorbidity and concomitant medications of chronic hepatitis C (CHC) patients were extracted from Chinese Health Insurance database. Drug-drug interactions (DDIs) were calculated by integrated above data and confirmed by using Liverpool DDI website. Based on those data, experts propose consensus on management of drug-drug interaction with direct-acting antiviral agents in chronic hepatitis C, including pre-treatment, on-treatment, and post-treatment.
